Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours
Disease area: Thoracic oncology

Abstract

Growing body of evidence suggests that molecular markers are an important prognostic marker for non-small lung cancer (NSCLC). Using targeted therapy based on these markers leads to improved outcomes in lung adenocarcinoma. However, progress of targeted therapy in squamous lung cancer is still modest. p16(ink) protein acts as tumor suppressor and vascular endothelial growth factor (VEGF) promotes tumor angiogenesis.Purpose of this study was to evaluate the difference in p16(ink4) and VEGF expression between squamous and adenocarcinoma of the lung; to evaluate the relationship of p16(ink4) and VEGF expression to survival outcomes in NSCLC patients, and the difference of their prognostic values between squamous and adenocarcinoma subtypes.100 NSCLC patients (50 squamous and 50 adenocarcinoma) and 80 healthy individuals were included. p16(ink4) and VEGF proteins were immunohistochemicaly detected on formalin-fixed tissues. One- and 2-year progression-free survival (PFS) and overall survival (OS) were observed.p16(ink4) expression was significantly lower in squamous type compared to adenocarcinoma. In both squamous and adenocarcinoma, high VEGF expression correlated with worse 1-year PFS and OS, but only with worse 2-year PFS. Low p16(ink4) expression correlated with worse 1- and 2-year PFS, as well as OS, in both NSCLC subtypes. In squamous lung cancer p16(ink4) expression was an independent negative prognostic marker.Our study confirms the difference of p16(ink4) protein expression in squamous and adenocarcinoma of the lung. Besides anti-VEGF therapy, the regulation of p16(ink4) expression could have a therapeutic potential in NSCLC, especially in squamous lung cancer.

Rating:

Share or cite this content

Citations should be made in the following way:
R. Sejdinovic, E. Jusufovic, F. Ljuca, D. Keser, M. Osmic, B. Prnjavorac, E. Zukic, E. Budisin, J. Alidzanovic (Tesanj, Zenica, Tuzla, Sarajevo, Bosnia And Herzegovina; Sremska Kamenica, Republic Of Serbia). Differences in expression and prognostic values of p16(ink) and VEGF in squamous and adenocarcinoma of the lung. Eur Respir J 2014; 44: Suppl. 58, 517

Member's Comments

No comment yet.

Related content which might interest you: Significance of EGFR expression patterns in patients with non-small cell lung cancer – Evaluation on protein- and/or gene level? Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours Year: 2014 beta-F1-ATPase expression as a prognostic factor for resected non-small cell lung cancer Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer Year: 2013 Immunohistochemical expression of nuclear factor kappa-B/p65 and cyclooxygenase-2 in non-small cell lung cancer patients: Prognostic value and impact on survival Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours Year: 2014 Simultaneous EGFR and VEGF alterations in non-small cell lung carcinoma based on tissue microarrays Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours Year: 2014 Serum IL-33 as a diagnostic and prognostic marker in non- small cell lung cancer Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours Year: 2014 Clinicopathological prognostic factors in operated for pulmonary carcinoid tumor patients Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours Year: 2014 LATE-BREAKING ABSTRACT: Decreased sirtuin expression in squamous cell carcinoma compared to adenocarcinoma Source: International Congress 2014 – New technologies and biomarkers in lung disease Year: 2014 Expression analysis of miR-21 in Bulgarian patients with non-small cell lung cancer Source: International Congress 2016 – Prognostic variables in lung cancer I Year: 2016 Molecular profiling of lung squamous carcinogenesis Source: Annual Congress 2013 –Biology and molecular pathology of lung cancer Year: 2013 Prognostic value and functional characterization of miR-141 and miR-200c expression levels in resected NSCL Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours Year: 2014 Clinical significance of erythropoietin (Epo) and its receptor (EpoR) in non-small cell lung carcinoma Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014 Prognostic value of EGFR mutation in NSCLC in surgical stage Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014 Evaluation of predictive and therapeutic value of WSX1/IL27 axis in non-small cell lung cancer (NSCLC) Source: International Congress 2015 – Cell biology of lung cancer and new biomarkers Year: 2015 The value of miR221 and miR222 as a biomarker in non small cell lung cancer Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours Year: 2014 Second primary lung cancer in squamous NSCLC patients: The Nancy Biobank's database Source: International Congress 2014 – Epidemiology, pathogenesis and quality management of thoracic tumours Year: 2014 Significance of expression of TGF-β in pulmonary metastasis in non-small cell lung cancer tissues Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours Year: 2015 Breast metastasis from primary EGFR-mutated lung carcinoma or primary tumor? Source: International Congress 2016 – Basic science and case reports in lung cancer Year: 2016 The prognostic impact of PD1 and PDL1 expression in non-small cell lung cancer Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours Year: 2015 Molecular signatures of non-small cell lung cancer (NSCLC) obtained from gene expression profiling of the benign bronchial mucosa of smokers with and without NSCLC Source: Annual Congress 2013 –Biology and molecular pathology of lung cancer Year: 2013 Methilation status in EBUS-NA samples of lung cancer Source: International Congress 2014 – Improving diagnosis of thoracic tumours Year: 2014